Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ajhp/54.1.52 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fullerenol nanoparticles and AMF application for optimization of Brassica napus L. resilience to lead toxicity through physio-biochemical and antioxidative modulations.
Sci Rep
December 2024
College of Agriculture and Biotechnology, Zhejiang University, Hangzhou, 310058, China.
Crop plants are severely affected by heavy metals (HMs), leading to food scarcity and economical loss. Lead (Pb) is outsourced by use of lead-based fertilizers, batteries, mining, smelting and metal processing. It significantly reduces growth, development and yield of crops cultivated on contaminated sites.
View Article and Find Full Text PDFMulticenter Clinical Performance Evaluation of the NeuMoDx™ CT/NG Assay 2.0.
Sex Transm Dis
December 2024
QIAGEN Ltd, Hathersage Road, Manchester, M13 0BH, UK.
Background: Given the continued increases in rates of both Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infection, additional diagnostic assays may be useful in increasing access to testing for these sexually transmitted infections. We evaluated the performance of the NeuMoDx™ CT/NG Assay 2.0 on the NeuMoDx-96 and NeuMoDx-288 Molecular Systems.
View Article and Find Full Text PDFTesting BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology.
Clin Genitourin Cancer
February 2025
Department of Oncology, University of Turin, AOU San Luigi Gonzaga, 10043 Orbassano, Italy.
Article Synopsis
- About 20% of prostate cancer patients have alterations in HRR genes like BRCA1/2, which are important biomarkers for treatment with PARP inhibitors like Olaparib, currently approved for metastatic castration-resistant prostate cancer (mCRPC) with BRCA mutations in Italy.
- A survey of 108 oncologists revealed that only 52.8% regularly test all metastatic prostate cancer patients for BRCA mutations, and many face challenges such as long wait times and unclear procedures.
- These obstacles hinder the effective implementation of genetic testing, limiting access to personalized PARP inhibitor treatment and highlighting the need for improved molecular testing processes in clinical settings.
Indirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.
Adv Ther
January 2025
EVERSANA™, Burlington, ON, Canada.
Introduction: Indirect treatment comparisons (ITCs) evaluate novel treatments compared to appropriate comparators when direct evidence is unavailable or infeasible. The objective of this study was to highlight the prevalence of different ITC methods in oncology drug submissions and to provide insights into how ITCs have been used in recent regulatory approval, reimbursement recommendations, or pricing decisions across various regions and diverse assessment frameworks.
Methods: A targeted literature review was conducted to identify assessment documents for oncology drug submissions that included ITCs.
Ergot alkaloids: comparison of extraction efficiencies for their monitoring in several cereal-solvent combinations by UPLC-MS/MS.
Mycotoxin Res
February 2025
Analytical Food Science, Barilla G. E R. Fratelli S.P.A, Via Mantova, 166-43122, Parma, Italy.
To date, there are more than 80 ergot alkaloids identified; their distribution depends on different factors (e.g. geographic regions, host plants).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!